Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts

Group 1 - Assembly Biosciences, Inc. (NASDAQ: ASMB) released results from its phase 1b study of ABI-5366, a long-acting helicase-primase inhibitor for treating recurrent genital herpes [2] - The study results are significant for the treatment of patients suffering from recurrent genital herpes, indicating potential advancements in the pharmaceutical sector [2] Group 2 - The Biotech Analysis Central service offers a comprehensive analysis of various pharmaceutical companies, including a library of over 600 articles and a model portfolio of small and mid-cap stocks [2]